Treatment with EA may reduce the blood ammonia level, modulate inflammatory factors, ameliorate brain necrosis and apoptosis, and improve cognitive impairment through regulation of TLR4/MyD88/NF-κB and p38MAPK/STAT3 signaling pathways. The gene discussed is STAT3; the disease is Cognitive impairment.